ELICHENS
17.12.2020 15:02:09 CET | Business Wire | Press release
Dry ice, frozen carbon dioxide (CO2), maintains the Covid-19 vaccines at very low temperatures. As dry ice warms and changes from a frozen to a gaseous state, it creates an excessive presence of CO2 gas which could affect the health of workers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201217005182/en/
eLichens’ Cranberry NDIR (Non-Dispersive-Infra-Red) CO2 sensor is designed to serve such critical applications. By continuously monitoring CO2 levels and triggering alerts when high thresholds are exceeded our CO2 sensor integrated into the Honeywell BW™ SOLO CO2 product has become essential for workers' protection when manipulating large volumes of dry ice as it prevents toxic health effects such as asphyxia, dizziness, disorientation, fatigue and convulsions.
“We are very proud that eLichens CO2 sensor has been selected by Honeywell for their BW™ SOLO CO2 product to monitor and alert workers in case of unsafe conditions and minimize disruptions throughout the Covid-19 vaccine cold supply chain,” said Wahid Issa, Chief Executive Officer of eLichens.
eLichens’ Cranberry 1-series NDIR sensor is the smallest industrial grade CO2 sensor on the market. It is high performance, dual channel and ultra-low power.
“Working closely with eLichens we quickly saw the technical benefits of their technology and that this was a great fit for our BW™ SOLO CO2 product giving us a sensor that performs in extreme conditions and a reliability that the end user can trust,” said Richard Dunn, Senior Offering Management Leader at Honeywell.
More information about the Honeywell BW™ SOLO at: https://www.honeywellanalytics.com/en/products/BW-Solo
About eLichens (www.elichens.com ):
Founded in December 2014, eLichens mission is to pioneer the Smart Sensor Network to enable Air Quality Sensing Services through its data fusion, cloud models and analytics, for a safer and eco-friendlier environment. The company relies on a portfolio of patents, know-how and skills that enable complete air quality and multi-gas (CO2, LEL, CH4, PM, refrigerants, …) detection solutions, addressing Industrial Safety, Gas Utilities and Smart Home/City markets. eLichens has its headquarters in Grenoble, France with offices in Paris, France and in the Silicon Valley California, USA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201217005182/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Garvan Institute of Medical Research Joins Parse Biosciences’ Certified Service Provider Network15.7.2026 22:00:00 CEST | Press release
Researchers across Asia-Pacific gain a new option for high-quality single cell sequencing through Garvan's Evercode WT services Parse Biosciences, a QIAGEN company, and the leader in scalable and accessible single cell sequencing, today announced that the Genomics Platform Core Facility within the Garvan Institute of Medical Research has joined its Certified Service Provider (CSP) Program. The partnership broadens access to high-quality, scalable single cell sequencing across Australia, the wider Asia-Pacific region, and beyond. Garvan is one of Australia's preeminent medical research institutions, with the Genomics Platform having deep experience in cell sorting, capture, and sequencing. As a Certified Service Provider, Garvan will offer Parse's Evercode WT kits to researchers across the region. "We see a growing number of requests for Parse projects and find the technology easy to implement and run, generating great data," said Chris O'Keeffe, Cellular Genomics Lead at the Garvan Ins
Grafana Labs Named a Leader in 2026 Gartner® Magic Quadrant™ for Observability Platforms and Positioned Furthest in Completeness of Vision15.7.2026 20:21:00 CEST | Press release
Named a Leader for the third consecutive year and placed furthest in vision for the second year in a row, the company has had a landmark year of innovation as observability becomes essential infrastructure for teams building and running AI at scale. Grafana Labs, the company behind the open observability cloud, today announced it has been named a Leader in the Gartner® Magic Quadrant™ for Observability Platforms for the third consecutive year, and positioned furthest on the Completeness of Vision axis for the second year running. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260715814984/en/ 2026 Gartner® Magic Quadrant™ for Observability Platforms We believe this placement reflects where the market is headed: toward open, composable observability that helps teams in the AI era understand systems that are increasingly complex and agentic, and rapidly scaling thanks to AI-assisted engineering. A Platform Built for the AI Era
Spectro Cloud Raises $100 Million Series D to Help Customers Move AI Infrastructure Into Production Across Enterprise, Public Sector, Neocloud and Sovereign Cloud Environments15.7.2026 18:20:00 CEST | Press release
Growth Equity at Goldman Sachs Alternatives leads oversubscribed round with strategic participation from AMD Ventures, Ericsson, LG Technology Ventures, and Maximus as organizations look to turn AI silicon into business outcomes Spectro Cloud, a leading provider of AI infrastructure management software, today announced it has raised more than $100 million in an oversubscribed Series D funding round led by Growth Equity at Goldman Sachs Alternatives, with strategic participation from AMD Ventures, Ericsson, LG Technology Ventures, and Maximus. The new funding brings Spectro Cloud’s total capital raised to $260 million and will accelerate the company’s mission to help enterprises, public sector organizations, neoclouds and sovereign clouds build and operate production AI infrastructure with greater control over cost, security and governance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260715551858/en/ Spectro Cloud raises $
K-Beauty Goes Global: Sales Surge 53% as Korean Innovation Reshapes Beauty Growth15.7.2026 16:00:00 CEST | Press release
New NIQ data shows K-Beauty value sales rose 53% year-over-year and 131% over two years, underscoring how regional beauty trends, social commerce and ingredient-led innovation are reshaping global beauty growth. NIQ (NYSE: NIQ), a global leader in consumer intelligence, today released new findings showing K-Beauty has become a rapidly growing global beauty segment, with value sales up 53% year-over-year and 131% over the past two years. The data points to a broader shift in beauty growth, as regional innovation, social commerce and digitally driven consumer demand increasingly shape what scales globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260715867578/en/ K-Beauty accelerates across global markets In its latest report, K-Beauty Goes Global, NIQ shows how Korean beauty is reshaping consumer expectations, accelerating innovation cycles and redefining competitive dynamics across the global beauty market. What began
Viz.ai to Support the MINUTE Trial, a Landmark Multicenter Study Evaluating the SCUBA Technique for the Treatment of Intracerebral Hemorrhage15.7.2026 15:00:00 CEST | Press release
Viz Neuro™ Suite, including Viz ICH™ and Viz ICH Plus™, to facilitate rapid detection and care coordination for patients with basal ganglia hemorrhage across trial sites nationwide. Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced its support for the Minimally Invasive Neurosurgery Trial for Ultra-early Treatment (MINUTE) Trial, a prospective, multicenter, randomized study evaluating whether the SCUBA technique, an endoscopic, catheter-based approach for ultra-early evacuation of basal ganglia intracerebral hemorrhage (BGH), is a promising alternative to standard medical management to potentially improve functional patient outcomes. The study aims to initiate both randomization and surgical intervention within 120 minutes of key clinical time points, reflecting the urgent nature of intracerebral hemorrhage care. Participating sites will have the ability to leverage the Viz Neuro Suite platform, including Viz ICH and Viz ICH Plus, to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom